Axial Spondyloarthritis

Axial spondyloarthritis (axSpA) is a chronic inflammatory rheumatic disease centered on the sacroiliac joints and spine. It includes radiographic disease, historically termed ankylosing spondylitis, and non-radiographic disease. Persistent inflammatory back pain, stiffness, fatigue, and functional limitations can substantially affect mobility, work, and quality of life. Diagnosis is clinical and supported by imaging, laboratory findings, and specialist assessment; no single test identifies every case.

Care is shifting from prolonged symptom management toward earlier recognition, structured assessment, and treatment aimed at sustained disease control. Greater awareness of inflammatory back-pain features, improved use of magnetic resonance imaging, and attention to extra-articular manifestations such as uveitis, psoriasis, and inflammatory bowel disease can support more timely referral. Management is also becoming more multidisciplinary, combining pharmacologic treatment with exercise, rehabilitation, smoking cessation, and monitoring of cardiovascular, bone, and psychosocial health.

Artificial intelligence can support axSpA care by identifying patterns in clinical notes, imaging, laboratory results, and patient-reported outcomes. Potential applications include triaging referrals, assisting radiographic or magnetic-resonance-image interpretation, flagging patients with delayed diagnosis, and monitoring treatment response. These tools require representative training data, prospective validation, explainable outputs, privacy safeguards, and clinician oversight because inflammatory changes may be subtle and imaging findings can overlap with mechanical or degenerative conditions.

North America generally benefits from established rheumatology services and advanced imaging, although insurance restrictions, specialist availability, and uneven access can delay care. Europe combines strong clinical expertise with variation among national health systems, reimbursement rules, and referral pathways. Asia-Pacific spans highly developed and resource-constrained settings, with differences in awareness, imaging capacity, and specialist density. Latin America faces uneven access to biologic therapies, diagnostic imaging, and multidisciplinary services. In the Middle East, urban concentration of specialist care and differing health-system capacity shape access. Africa often encounters limited rheumatology coverage, diagnostic delays, and constrained access to advanced imaging and targeted therapies.

ASEAN countries would benefit from stronger referral networks, standardized education, and broader access to imaging and specialist assessment. BRICS members have substantial variation in health-system capacity, making locally adapted diagnostic pathways and equitable treatment access important. The European Union can build on cross-border clinical standards while addressing national differences in reimbursement and service delivery. G7 systems generally possess advanced research and clinical infrastructure but still face delayed diagnosis, aging populations, and affordability or access barriers. GCC countries often have concentrated specialist capacity and opportunities for coordinated regional pathways. NATO members may benefit from common approaches to musculoskeletal health, military readiness, and continuity of care across service systems.

Australia and Canada face geographic and specialist-access challenges despite established healthcare systems. Brazil, Mexico, India, China, and Russia must address substantial regional variation in rheumatology coverage, imaging, and treatment access. France, Germany, Italy, Spain, and the United Kingdom have mature specialist services but differ in referral routes, reimbursement, and adoption of advanced therapies. Japan and South Korea combine sophisticated medical infrastructure with opportunities to improve recognition of non-radiographic disease and care coordination. In the United States, broad clinical capability coexists with insurance complexity, affordability concerns, and disparities in specialist access. Across all listed countries, earlier referral and consistent treat-to-target monitoring remain practical priorities.

Leaders should invest in validated educational programs that help primary-care clinicians and patients recognize inflammatory back pain and associated conditions. Diagnostic strategies should combine referral tools, imaging protocols, and rheumatologist review rather than relying on isolated biomarkers. Treatment programs should support shared decision-making, adherence, exercise, rehabilitation, and systematic monitoring of disease activity and safety. Organizations developing digital or artificial-intelligence solutions should validate performance across demographic groups and healthcare settings, integrate human oversight, and demonstrate improvements in diagnostic timeliness or patient outcomes. Access initiatives should address affordability, geographic gaps, and continuity of care while generating real-world evidence on long-term effectiveness and safety.

This executive summary uses a structured review of established clinical definitions, diagnostic principles, treatment pathways, health-system considerations, and documented technology applications relevant to axSpA. Evidence should be triangulated across peer-reviewed studies, clinical guidelines, regulatory or public-health publications, and validated epidemiological or outcomes research. Findings are organized by care transformation, artificial-intelligence use, geography, and population grouping. Interpretation should distinguish radiographic and non-radiographic disease, separate evidence from emerging possibilities, and account for differences in healthcare access, coding, imaging practice, and referral patterns. No market estimates, forecasts, shares, or company-specific claims are used.

Axial spondyloarthritis care is advancing through earlier recognition, more precise imaging, targeted treatment, and broader attention to lifelong functional health. The greatest practical gains will come from connecting primary care, radiology, rheumatology, rehabilitation, and relevant specialty services; reducing diagnostic and access delays; and applying artificial intelligence only where it is clinically validated and responsibly governed. Systems that combine equitable access with consistent disease monitoring can better protect mobility, participation, and quality of life for people living with axSpA.